iPSC-Derived Regenerative Medicines Development Platform
The evolution of induced pluripotent stem cells (iPSCs) has injected boundless vitality into the advancement of regenerative medicine. Serving as valuable models for drug screening and disease treatment, iPSCs have been widely exploited in research related to rare diseases. As a leading company specializing in the development of iPSC-derived regenerative medicines, our company is dedicated to providing customers with iPSC-derived regenerative medicines development services.
What is iPSCs?
Induced pluripotent stem cells (iPSCs) are obtained by gradually introducing several relevant genes into somatic cells. iPSCs exhibit remarkable similarities to embryonic stem cells (ESCs) in terms of morphology, expression of genes and proteins, epigenetic modifications, cell proliferation capacity, pluripotency and teratoma formation ability. iPSCs possess unlimited proliferation and multi-lineage differentiation potential, allowing them to generate multiple types of terminal differentiated cells and tissues. The discovery of induced pluripotent stem cells has completely addressed the issues of cell source and ethics problems in ESCs clinical applications. It has provided robust support for personalized therapy, greatly overcame the challenges of immune rejection in stem cell therapy, and opened up a whole new field in regenerative medicine.
iPSC-Derived Regenerative Medicines
Certain rare diseases are able to be repaired and regenerated by organ or cell transplantation. However, conventional cell or organ transplantation has serious problems with insufficient donor sources and immune rejection, as well as ethical obstacles. Discovery of induced multipotent stem cells opens a new chapter in regenerative medicine and solve ethical problem. The emergence of new technologies has further enhanced the safety of iPSCs, laying a solid foundation for clinical research and applications of iPSCs in rare diseases. At present, iPSCs have been applied in the treatment of several rare diseases and have achieved great treatment progress.
Induced pluripotent stem cells (iPSCs) have been widely researched and has shown tremendous clinical therapeutic potential. Our company offers iPSC-derived regenerative medicines development services based on our advanced technology and professional team. Our services are included but not limited as follows:
- Cell isolation
- Reprogramming solution
- Gene engineering
- Expansion & culture
- Cell phenotypes
- Secretion characteristics
- Culture heterogeneity
- Single cell sequencing
- Bulk RNA-seq
- Sanger sequencing
- Whole-genome sequencing
iPSC-Derived Organoids Services
- Type-specific organoid
- Drug screening
iPSC-Derived Regenerative Medicines Development Workflow
As an advanced biotechnology company, our company committed to providing idea solutions to optimize your iPSC-derived regenerative medicines development for rare diseases. Our research team will assist you in advancing your research, saving your time and effort. If you are interested in our services, please contact us for more details.
- Aboul-Soud MAM, Alzahrani AJ, Mahmoud A. Induced Pluripotent Stem Cells (iPSCs)-Roles in Regenerative Therapies, Disease Modelling and Drug Screening. Cells, 2021,10(9):2319.
- Lee H, Son MY. Current Challenges Associated with the Use of Human Induced Pluripotent Stem Cell-Derived Organoids in Regenerative Medicine. Int J Stem Cells, 2021, 14(1):9-20.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.